A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Recruiting

Phase 1

ALTA3263A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Sponsor:

Alterome Therapeutics, Inc.

Code:

NCT06835569

Conditions

Cancer

PDAC - Pancreatic Ductal Adenocarcinoma

NSCLC (Non-small Cell Lung Cancer)

CRC (Colorectal Cancer)

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ALTA3263

cetuximab

mFOLFOX6

Pembrolizumab

Pemetrexed + Cisplatin /Carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-18. This information was provided to ClinicalTrials.gov by Alterome Therapeutics, Inc. on 2026-06-10.